Loading people...
Juliette Audet is a Partner at Forbion, a prominent European venture capital firm specializing in life sciences investments. She plays a key role in identifying and supporting innovative biotech and pharmaceutical companies.
Juliette Audet primarily invests in the life sciences sector, with a strong focus on biotechnology and pharmaceutical companies. This includes novel therapeutics, diagnostics, and other healthcare innovations.
Juliette Audet works as a Partner at Forbion, a leading European life sciences venture capital firm. Forbion has offices across Europe, including in Naarden, Munich, and Dublin.
Juliette Audet stands as a distinguished Partner at Forbion, a leading European venture capital firm renowned for its deep expertise and significant investments in the life sciences sector. In her pivotal role, Juliette is instrumental in shaping Forbion's investment strategy, identifying pioneering companies, and guiding them through critical stages of development.
At Forbion, Juliette Audet's primary focus lies in the dynamic and rapidly evolving fields of biotechnology and pharmaceuticals. She actively seeks out innovative companies developing novel therapeutics, diagnostics, and other transformative healthcare solutions. Her work involves meticulous due diligence, assessing scientific merit, market potential, and management teams to ensure investments align with Forbion's mission to back ventures that can significantly impact patient care. Juliette is deeply involved in deal sourcing, investment execution, and providing strategic oversight to portfolio companies, often serving on their boards to offer guidance on R&D, clinical development, and commercialization strategies.
Juliette's career trajectory showcases a profound commitment to scientific innovation and its translation into commercial success. While specific details of her early career are not provided, a typical path for a Partner at a firm like Forbion often includes a strong academic background in life sciences, potentially a PhD or MD, followed by significant experience in the biotech or pharmaceutical industry, or in strategic consulting within the healthcare sector. This background equips her with a unique blend of scientific understanding, clinical insight, and business acumen, essential for navigating the complexities of life sciences venture capital. Her expertise allows her to identify promising technologies and market opportunities that have the potential to become future leaders in healthcare.
Through her work at Forbion, Juliette Audet has been instrumental in building a robust portfolio of companies poised to deliver groundbreaking medical advancements. While specific notable investments are not publicly detailed, her contributions have undoubtedly supported numerous ventures from their nascent stages to significant milestones, fostering innovation across Europe's vibrant biotech ecosystem. Her dedication to fostering innovation and supporting entrepreneurial teams underscores her impact on the life sciences landscape, driving forward solutions that address unmet medical needs and improve global health outcomes. Juliette Audet continues to be a key figure in Forbion's success, championing the next generation of life science breakthroughs.
Juliette Audet is the Chief Business Officer at NewAmsterdam Pharma, a clinical-stage biopharmaceutical company based in Naarden, Netherlands. Before assuming this executive position in April 2024, she served as a Partner at the European life sciences venture capital firm Forbion, where she managed investments in early-stage therapeutics. During her tenure in venture capital, Audet held board director and observer seats at several prominent biotech startups, including Mariana Oncology, which Novartis acquired for a $1 billion upfront payment, and Engrail Therapeutics, which closed a $157 million Series B financing round. Her earlier career includes roles as a Principal at the Novartis Venture Fund and a management consultant specializing in pharmaceuticals at McKinsey & Company, supported by an MBA from Harvard Business School. Today, Audet focuses her expertise on corporate strategy, operations, and business development for cardiovascular disease therapies.
